Latest Breaking News On - Michigan angel fund - Page 4 : comparemela.com

Cybersecurity business BitLyft raises $1 million funding round

AstraZeneca's Alexion taps DNA profiler Genomenon for rare disease diagnoses

Follow the Money: Single-Cell Multiomics, Data Networks, Security

April 1, 2021 By Bio-IT World Staff April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.   $969M Investment Fund for Early to Late-Stage Companies Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.